PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
July 24, 2026Journal of Clinical Laboratory AnalysisOpen Access

Plasma Proteomic Profiling Identifies Candidate Biomarkers for Pancreatic Ductal Adenocarcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LXLelang XiangYJYi JinRHRan Hu

Discussion

Loading...

Member takes

Overview

Randomized trial identifies candidate biomarkers for pancreatic ductal adenocarcinoma, suggesting earlier detection possibilities.

Key Points

  • This research aims to identify candidate biomarkers for early detection of pancreatic ductal adenocarcinoma (PDAC) through plasma proteomic profiling.
  • Analyzed plasma samples from 99 PDAC patients and 30 healthy controls using data-independent acquisition (DIA) proteomics.
  • Identified differentially expressed proteins and conducted functional enrichment analysis.
  • Validated selected biomarkers using ELISA in an independent subset.
  • Identified 52 differentially expressed proteins between PDAC patients and healthy controls.
  • ELISA validation showed higher plasma levels of Cathepsin S, CTRB2, MARCO, PIGR, PRDX6, REG1A, Trypsin-2, and PEP-FAP in PDAC patients.
  • ROC analyses indicated moderate-to-good discriminatory performance for several candidate biomarkers.

Cite This Study

Xiang et al. (2026) studied this question.

synapsesocial.com/papers/6a6301a6395161722cd162f7https://doi.org/10.1002/jcla.70313
View Full Paper
Ask AI
Bookmark
Share